Media coverage about Chemours (NYSE:CC) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chemours earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the specialty chemicals company an impact score of 46.6331421027877 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news stories that may have impacted Accern’s analysis:

Shares of Chemours (CC) traded down $0.07 during trading on Monday, reaching $48.84. 2,675,730 shares of the company traded hands, compared to its average volume of 1,770,000. The company has a market cap of $9,030.00 and a P/E ratio of 12.52. The company has a debt-to-equity ratio of 4.74, a current ratio of 2.12 and a quick ratio of 1.55. Chemours has a one year low of $32.09 and a one year high of $58.08.

Chemours (NYSE:CC) last announced its quarterly earnings results on Wednesday, February 14th. The specialty chemicals company reported $1.19 EPS for the quarter, topping the consensus estimate of $0.95 by $0.24. The business had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.55 billion. Chemours had a net margin of 12.06% and a return on equity of 115.54%. The business’s quarterly revenue was up 19.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.08 EPS. analysts anticipate that Chemours will post 5.16 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Thursday, February 15th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $0.68 annualized dividend and a yield of 1.39%. This is a boost from Chemours’s previous quarterly dividend of $0.03. Chemours’s payout ratio is presently 17.44%.

Chemours announced that its Board of Directors has approved a stock repurchase program on Friday, December 1st that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the specialty chemicals company to reacquire shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Several brokerages recently weighed in on CC. UBS Group upped their target price on shares of Chemours from $50.00 to $59.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Barclays upped their target price on shares of Chemours from $55.00 to $58.00 and gave the stock an “overweight” rating in a report on Monday, November 6th. Morgan Stanley began coverage on shares of Chemours in a report on Tuesday, January 30th. They issued an “equal weight” rating and a $57.50 target price for the company. Zacks Investment Research downgraded shares of Chemours from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, Goldman Sachs Group downgraded shares of Chemours from a “buy” rating to a “neutral” rating and set a $55.00 target price for the company. in a report on Wednesday, December 6th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $57.85.

In other Chemours news, insider Christian W. Siemer sold 15,088 shares of the business’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $47.37, for a total value of $714,718.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.14% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Chemours (CC) Share Price” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at

Chemours Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Insider Buying and Selling by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with's FREE daily email newsletter.